ATF3 expression improves motor function in the ALS mouse model by promoting motor neuron survival and retaining muscle innervation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 4, 2014, Pages 1622-1627

  Seijffers, Rhona ^a,b   Zhang, Jiangwen ^c   Matthews, Jonathan C ^d   Chen, Adam ^d   Tamrazian, Eric ^d,e   Babaniyi, Olusegun ^a,b   Selig, Martin ^f   Hynynen, Meri ^d   Woolf, Clifford J ^a,b   Brown Jr , Robert H ^d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e ST GEORGE S UNIVERSITY   (Grenada)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DISEASE DURATION; GASTROCNEMIUS MUSCLE; MORTALITY; MOTONEURON; MOTOR PERFORMANCE; MOUSE; MUSCLE ATROPHY; MUSCLE DENERVATION; MUSCLE INNERVATION; MUSCLE MASS; MUSCLE STRENGTH; NERVE SPROUTING; NEUROMUSCULAR SYNAPSE; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACTIVATING TRANSCRIPTION FACTOR 3; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; MICE; MOTOR NEURONS; MUSCLE, SKELETAL; SUPEROXIDE DISMUTASE;

EID: 84893357959     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1314826111     Document Type: Article

References (46)

1. Pasinelli P, Brown RH (2006) Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat Rev Neurosci 7(9):710-723.
2. Mitchell JD, Borasio GD (2007) Amyotrophic lateral sclerosis. Lancet 369(9578): 2031-2041.
3. Rothstein JD (2009) Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 65(Suppl 1):S3-S9.
4. Lagier-Tourenne C, Cleveland DW (2009) Rethinking ALS: The FUS about TDP-43. Cell 136(6):1001-1004.
5. Bruijn LI, Miller TM, Cleveland DW (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27:723-749.
6. Gurney ME, et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264(5166):1772-1775.
7. Bruijn LI, Cudkowicz M (2006) Therapeutic targets for amyotrophic lateral sclerosis: Current treatments and prospects for more effective therapies. Expert Rev Neurother 6(3):417-428.
8. Ilieva H, Polymenidou M, Cleveland DW (2009) Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 187(6):761-772.
9. Papadimitriou D, et al. (2010) Inflammation in ALS and SMA: Sorting out the good from the evil. Neurobiol Dis 37(3):493-502.
10. Fischer LR, Glass JD (2007) Axonal degeneration in motor neuron disease. Neurodegener Dis 4(6):431-442.
11. Gordon T, Hegedus J, Tam SL (2004) Adaptive and maladaptive motor axonal sprouting in aging and motoneuron disease. Neurol Res 26(2):174-185.
12. Fischer LR, et al. (2004) Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp Neurol 185(2):232-240.
13. Kanning KC, Kaplan A, Henderson CE (2010) Motor neuron diversity in development and disease. Annu Rev Neurosci 33:409-440.
14. Hai T, Hartman MG (2001) The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: Activating transcription factor proteins and homeostasis. Gene 273(1):1-11.
15. Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U (1999) ATF3 and stress responses. Gene Expr 7(4-6):321-335.
16. Thompson MR, Xu D, Williams BR (2009) ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med (Berl) 87(11):1053-1060.
17. Hunt D, Raivich G, Anderson PN (2012) Activating transcription factor 3 and the nervous system. Front Mol Neurosci 5:7.
18. Seijffers R, Allchorne AJ, Woolf CJ (2006) The transcription factor ATF-3 promotes neurite outgrowth. Mol Cell Neurosci 32(1-2):143-154.
19. Seijffers R, Mills CD, Woolf CJ (2007) ATF3 increases the intrinsic growth state of DRG neurons to enhance peripheral nerve regeneration. J Neurosci 27(30):7911-7920.
20. Francis JS, Dragunow M, During MJ (2004) Over expression of ATF-3 protects rat hippocampal neurons from in vivo injection of kainic acid. Brain Res Mol Brain Res 124(2):199-203.
21. Nakagomi S, Suzuki Y, Namikawa K, Kiryu-Seo S, Kiyama H (2003) Expression of the activating transcription factor 3 prevents c-Jun N-terminal kinase-induced neuronal death by promoting heat shock protein 27 expression and Akt activation. J Neurosci 23(12):5187-5196.
22. Liang Y, et al. (2009) ATF3 plays a protective role against toxicity by N-terminal fragment of mutant huntingtin in stable PC12 cell line. Brain Res 1286:221-229.
23. Pearson AG, et al. (2003) ATF3 enhances c-Jun-mediated neurite sprouting. Brain Res Mol Brain Res 120(1):38-45.
24. Lindwall C, Dahlin L, Lundborg G, Kanje M (2004) Inhibition of c-Jun phosphorylation reduces axonal outgrowth of adult rat nodose ganglia and dorsal root ganglia sensory neurons. Mol Cell Neurosci 27(3):267-279.
25. Zhang SJ, et al. (2011) A signaling cascade of nuclear calcium-CREB-ATF3 activated by synaptic NMDA receptors defines a gene repression module that protects against extrasynaptic NMDA receptor-induced neuronal cell death and ischemic brain damage. J Neurosci 31(13):4978-4990.
26. Wang L, et al. (2012) Increased inflammation and brain injury after transient focal cerebral ischemia in activating transcription factor 3 knockout mice. Neuroscience 220:100-108.
27. Tsujino H, et al. (2000) Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: A novel neuronal marker of nerve injury. Mol Cell Neurosci 15(2):170-182.
28. Offen D, et al. (2009) Spinal cord mRNA profile in patients with ALS: Comparison with transgenic mice expressing the human SOD-1 mutant. J Mol Neurosci 38(2):85-93.
29. Wang XS, Simmons Z, Liu W, Boyer PJ, Connor JR (2006) Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex. Amyotroph Lateral Scler 7(4):201-210.
30. Dangond F, et al. (2004) Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. Physiol Genomics 16(2): 229-239.
31. Jiang YM, et al. (2005) Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann Neurol 57(2):236-251.
32. Lederer CW, Torrisi A, Pantelidou M, Santama N, Cavallaro S (2007) Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC Genomics 8:26.
33. Vlug AS, et al. (2005) ATF3 expression precedes death of spinal motoneurons in amyotrophic lateral sclerosis-SOD1 transgenic mice and correlates with c-Jun phosphorylation, CHOP expression, somato-dendritic ubiquitination and Golgi fragmentation. Eur J Neurosci 22(8):1881-1894.
34. Saxena S, Cabuy E, Caroni P (2009) A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat Neurosci 12(5):627-636.
35. Lobsiger CS, Boillée S, Cleveland DW (2007) Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc Natl Acad Sci USA 104(18):7319-7326.
36. Malaspina A, et al. (2010) Activation transcription factor-3 activation and the development of spinal cord degeneration in a rat model of amyotrophic lateral sclerosis. Neuroscience 169(2):812-827.
37. Caroni P (1997) Overexpression of growth-associated proteins in the neurons of adult transgenic mice. J Neurosci Methods 71(1):3-9.
38. Tandan R, Bradley WG (1985) Amyotrophic lateral sclerosis: Part 2. Etiopathogenesis. Ann Neurol 18(4):419-431.
39. Bruijn LI, Cleveland DW (1996) Mechanisms of selective motor neuron death in ALS: Insights from transgenic mouse models of motor neuron disease. Neuropathol Appl Neurobiol 22(5):373-387.
40. Hegedus J, Putman CT, Gordon T (2007) Time course of preferential motor unit loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 28(2): 154-164.
41. Durand J, Amendola J, Bories C, Lamotte d'Incamps B (2006) Early abnormalities in transgenic mouse models of amyotrophic lateral sclerosis. J Physiol Paris 99(2-3): 211-220.
42. Reyes NA, et al. (2010) Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. J Clin Invest 120(10):3673-3679.
43. Gould TW, et al. (2006) Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci 26(34):8774-8786.
44. Kostic V, Jackson-Lewis V, de Bilbao F, Dubois-Dauphin M, Przedborski S (1997) Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 277(5325):559-562.
45. Vande Velde C, Garcia ML, Yin X, Trapp BD, Cleveland DW (2004) The neuroprotective factor Wlds does not attenuate mutant SOD1-mediated motor neuron disease. Neuromolecular Med 5(3):193-203.
46. Fischer LR, et al. (2005) The WldS gene modestly prolongs survival in the SOD1G93A fALS mouse. Neurobiol Dis 19(1-2):293-300.